Eli Lilly CEO David Ricks on Q2 results: Seeing unbelievable demand for Zepbound and Mounjaro
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion, demand outlook for Zepbound and Mounjaro, state of the weight loss drug competition, and more.
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion, demand outlook for Zepbound and Mounjaro, state of the weight loss drug competition, and more.
